Literature DB >> 2546565

Isoniazid-mediated irreversible inhibition of the myeloperoxidase antimicrobial system of the human neutrophil and the effect of thyronines.

J M van Zyl1, K Basson, R A Uebel, B J van der Walt.   

Abstract

During aerobic myeloperoxidase-catalysed oxidation of isoniazid at pH 7.8, compound III was generated. Oxidation of isoniazid or hydrazine sulphate at pH values of 6.5 or 7.8 in a myeloperoxidase-H2O2 system caused considerable haem loss, which was associated with compound III formation. Haem loss and also compound III formation could be inhibited when 8 microM thyroxine was included in the reaction mixtures. During the reaction with isoniazid, an intense pink-coloured pigment with maximum absorbance at 500 nm was formed which could be bleached with ascorbate or hypochlorous acid. The pigment was more stable at pH 7.8 than at pH 6.5. A similar pink colour was generated when a mixture of isoniazid and thyroxine in alkaline solution was irradiated with light of wavelength greater than 300 nm. A possible product of thyroxine oxidation, 3,5-diiodotyrosine, could not protect the enzyme against isoniazid-mediated haem loss and no colour formation was observed. Haem loss was most extensive when isoniazid was oxidised in a myeloperoxidase system at pH 7.8 in the presence of 0.1 M NaCl. Thyroxine (8 microM), however, could still inhibit haem loss under these conditions. A good correlation was found between haem loss and irreversible loss of peroxidase activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546565     DOI: 10.1016/0006-2952(89)90477-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Immunomodulation by antibacterial agents. Is it clinically relevant?

Authors:  M T Labro
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

3.  Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide.

Authors:  A J Kettle; C A Gedye; C C Winterbourn
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

Review 4.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

5.  Effects of four Indian medicinal herbs on Isoniazid-, Rifampicin- and Pyrazinamide-induced hepatic injury and immunosuppression in guinea pigs.

Authors:  Meghna-R Adhvaryu; Narsimha Reddy; Minoo H Parabia
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

6.  Inhibition of myeloperoxidase by benzoic acid hydrazides.

Authors:  A J Kettle; C A Gedye; M B Hampton; C C Winterbourn
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

7.  Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention.

Authors:  Michael J Davies
Journal:  J Clin Biochem Nutr       Date:  2010-12-28       Impact factor: 3.114

Review 8.  Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis.

Authors:  Seonghwan Hwang; Hwayoung Yun; Sungwon Moon; Ye Eun Cho; Bin Gao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-11       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.